Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 6450.83%.

  • Vistagen Therapeutics' EBIT Margin rose 107100.0% to 6450.83% in Q4 2025 from the same period last year, while for Dec 2025 it was 8847.85%, marking a year-over-year decrease of 9024300.0%. This contributed to the annual value of 11517.08% for FY2025, which is 84136000.0% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported EBIT Margin of 6450.83% as of Q4 2025, which was up 107100.0% from 7772.48% recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' EBIT Margin ranged from a high of 96633.33% in Q1 2025 and a low of 42802.56% during Q1 2022
  • For the 5-year period, Vistagen Therapeutics' EBIT Margin averaged around 2049.0%, with its median value being 5901.1% (2022).
  • Per our database at Business Quant, Vistagen Therapeutics' EBIT Margin plummeted by -413955500bps in 2022 and then skyrocketed by 1035595500bps in 2025.
  • Over the past 5 years, Vistagen Therapeutics' EBIT Margin (Quarter) stood at 2943.85% in 2021, then plummeted by -84bps to 5425.83% in 2022, then skyrocketed by 65bps to 1918.25% in 2023, then tumbled by -237bps to 6461.54% in 2024, then increased by 0bps to 6450.83% in 2025.
  • Its EBIT Margin was 6450.83% in Q4 2025, compared to 7772.48% in Q3 2025 and 6477.05% in Q2 2025.